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Abstract
Our recently discovered, selective, on-resin route to N(τ)-alkylated imidazolium-containing 
histidine residues affords new strategies for peptide mimetic design. In our current work, we 
demonstrate the use of this chemistry to prepare a series of macrocyclic phosphopeptides, in which 
imidazolium groups serve as ring-forming junctions. Interestingly, these cationic moieties 
subsequently serve to charge-mask the phosphoamino acid group that directed their formation. 
Neighbor-directed histidine N(τ)-alkylation opens the door to new families of 
phosphopeptidomimetics for use in a range of chemical biology contexts.
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INTRODUCTION
Modification of amino acid residues in biologically active peptides is a powerful tool for 
peptidomimetic design. These efforts can be greatly facilitated by transforming reactions 
that are selective and can be performed on solid-phase resin. Histidine is unique among the 
coded amino acids in having an imidazole ring with its two associated unsubstituted nitrogen 
atoms. Yet, exploiting histidine’s full potential for constructing peptidomimetics has been 
limited by the challenges of differentially functionalizing its N(π)- and N(τ)-positions. We 
have recently discovered the unanticipated ability of phosphoamino acids to direct the N(τ)-
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alkylation of proximal histidine residues already bearing an N(π)-substituent.1,2 These 
reactions are highly selective and can be conducted on fully protected peptides bound to 
solid-phase resin using Mitsunobu chemistries. The facile access to N(π), N(τ)-derivatized 
histidine residues affords as yet unexplored access to new families of peptidomimetics.
In the first practical application of this technology, we turned our attention to the sequence, 
“Ac-Pro-Leu-His-Ser-pThr-amide” (1, Figure 1), which is based on the C-proximal residues 
of the polo-box interacting protein 1 (PBIP1).3 The polo-like family of serine/threonine 
kinases (Plks) plays critical roles in cell cycle regulation, and antagonists of Plk1 are being 
developed as potential anticancer agents. The Plks are characterized as having polo-box 
domains (PBDs), which recognize phosphothreonine (pThr) and phosphoserine (pSer)-
containing sequences. In designing Plk1 PBD-binding antagonists, we had originally started 
with peptide 1 and found that adding long-chain alkylphenyl groups to the N(π) position of 
the His residue significantly enhances PBD-binding affinity.4 It was in subsequent studies 
with peptides of the form, “Ac-Pro-Leu-His*-Ser-pThr-amide” (2, Figure 1), where “His*” 
indicates the presence of an N(τ)–(CH2)8Ph group, that we first observed the preferential 
alkylation at the His N(τ)-position under Mitsunobu conditions.1 The formation of N(π), 
N(τ) bis-alkyl-His species was providential, since these peptides showed little or no 
diminution of PBD-binding affinity in in vitro assays, yet cellular potencies increased. This 
latter fact points to greater membrane transit made possible by intramolecular “charge-
masking” of one anionic pThr phosphoryl hydroxyl by the bis-alkyl-His imidazolium 
cation.5
We anticipated that N(τ)–alkylation could serve as a specific means of introducing structural 
diversification into the His imidazole side chain,2 and that such species could be employed 
for the construction of new classes of macrocyles. The importance of macrocyclization for 
constraining flexible ligands is widely recognized,6–9 and using the bifurcated His residue 
for ring closure could provide advantages in the design of macrocyclic PBD-binding 
peptides relative to more standard methodologies.10
RESULTS AND DISCUSSION
In order to examine the application of phospho-dependent His N(τ)–alkylation for 
macrocyclization, we designed three families of cyclized variants based on the parent 
sequence 1 (3 – 5, Figure 1). We incorporated the requisite His* residues under standard 
Fmoc conditions using our recently reported reagent.11 Macrocyclization was accomplished 
using ring-closing metathesis (RCM),12 which required preparing the appropriate open-
chain bis-alkenyl precursors. Amino-terminal alkenyl chains were appended either as ethers 
of R-4-hydroxy-Pro13 (for peptides 3) or as N-alkenoyl amides of Leu (peptides 4) and His* 
(peptides 5) (Figure 1).
Synthetic Approaches to Macrocycles 3, 4 and 5
Macrocycles 3a – 3d—Type 3 macrocycles were prepared in 18, 20, 22 and 24-member 
ring sizes (3a–3d, respectively, Figure 1). Resin-bound peptides having terminal Pro 
residues containing either an R-4-(4-pentenyloxy) or R-4-(2-propenyloxy) group (peptides 
6a and 6b, respectively) were subjected to pThr-directed Mitsunobu alkylations of their His* 
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N(τ)–nitrogens using a series of alkenyl alcohols.1,2 This afforded the requisite resin-bound 
bis-alkyl-His-containing peptides (7a–7d, Figure 2). On-resin microwave-assisted RCM ring 
closure using a common Pro residue having a 3-(4-pentenyloxy) group and the appropriate 
length N(τ)–alkenyl group was possible for the 20, 22 and 24-member macrocycles (8b–8d, 
respectively, Figure 2). Microwave irradiation can decrease reaction times, enhance catalyst 
performance and improve overall yields of RCM reactions.14–19 Typically, these reactions 
are conducted in a solvent combination of CH2Cl2: dimethylformamide (DMF) (10:1) using 
2nd Generation Grubbs20 or Hoveyda-Grubbs21 catalyst. The DMF facilitates peptide 
solubility and absorbs microwave radiation, while CH2Cl2 swells the resin.
During initial attempts to prepare the shorter 18-member macrocycle (3a) using 2-propenyl 
groups on both the 3-oxy-Pro and His*- N(τ) positions, it was found that on resin 
microwave-assisted RCM macrocyclization resulted in the loss of the Pro 3-alkoxy group, as 
was also the case when a Pro 3-butenyloxy group was employed. We rationalized that these 
losses could reflect Ru-catalyzed isomerization to a more labile 2-butenyl species.22 We 
circumvented these difficulties by using a 1-cinnamoyl group at the N(τ)–position (7a), 
which served as a 2-propenyl surrogate.23 In this fashion we obtained the desired 18-
membered macrocycle (11) by solution-phase RCM of the precursor peptide (10) at room 
temperature following cleavage from the resin (Figure 2).
Because cyclization under RCM conditions typically yields mixtures of E/Z products,24,25 
we eliminated geometric isomers by reducing the ring-closing double bonds. We examined 
diimine reduction, since this is compatible with both solution and solid-support 
protocols.26,27 We found that on-resin reduction of the 20-member macrocycle (8b) using 2-
nitrobenzenesulfonohydrazine (NBSH) and NEt326,27 resulted in poor conversion to the 
desired saturated macrocycle (9b). However, for the larger macrocycle ring sizes (22 and 24 
member; 8c and 8d, respectively), we achieved good conversion to the desired products (9c 
and 9d, respectively) using NBSH (20 equiv) and NEt3 (40 equiv) in CH2Cl2 with 
microwave irradiation (50 °C, 30 min) Subsequently, we found that cleavage of resin-bound 
8b to give 11b and hydrogenation in solution using H2 over 10% Pd•C in tetrahydrofuran 
(THF):DMF (10:1) at room temperature (overnight) gave very high-yield conversion to the 
saturated product (3b). Ring closure required for the synthesis of the shorter 18-member 
macrocycle (3a) could not be performed on-resin, due to lability of the Pro allyloxy group 
under the microwave conditions needed for the on-resin RCM reaction. However, RCM 
cyclization could be achieved in solution at room temperature on 10 following cleavage of 
7a from the resin. This yielded the unsaturated macrocycle (11a), which was hydrogenated 
(H2 over 10% Pd•C) to provide the desired final macrocycle 3a (Figure 2).
Macrocycles 4a – 4e—Type 4 macrocycles, based on the “Leu-His*-Ser-pThr” motif, 
were prepared similar to that described above for type 3 macrocycles. Precursor open-chain 
peptides for 18, 20, 22 and 24-member macrocyles (4b–4e, respectively) were assembled 
on-resin by initial N-terminal acylation with either hex-5-enoic acid (12a) or oct-7-enoic 
acid (12b). The peptides were subjected to pThr-directed Mitsunobu N(τ)–alkylation using 
the appropriate alkenyl alcohols, pent-4-ene-1-ol (for 13b and 13c); hept-6-ene-1-ol (for 
13d) and none-8-ene-1-ol (for 13e, Figure 3). On-resin RCM ring closures to the 
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corresponding peptides 14b–14e were carried out as indicated above, using Hoveyda-Grubbs 
2nd generation catalyst in CH2Cl2:DMF (10:1) with microwave irradiation (120 °C, 30 min). 
Diimine-mediated on-resin reduction of the resulting ring-forming double bonds yielded 
15b–15e [(20 and 40 equiv of NBSH and Et3N, respectively in CH2Cl2 with microwave 
irradiation (50 °C, 30 min)]. The final macrocyclic peptides (4b–4e) were obtained by resin 
cleavage and high performance liquid chromatography (HPLC) purification (Figure 3). We 
found in the attempted synthesis of the 16-member type 4 macrocycle using N-terminal 
acylation with but-3-enoic acid, that on-resin microwave-assisted RCM macrocylization 
resulted in ring-contraction (loss of –CH2–). This may have occurred by isomerization of the 
but-3-enoyl amide to the conjugated but-2-enoyl species prior to ring closure. Subsequent 
on-resin diimine reduction of the smaller, 15-member macrocycle also failed. However, 
cleavage of the peptide from the resin and followed by solution-phase reduction (H2 over 
10% Pd•C) gave the 15-member macrocycle (4a).
Macrocycles 5a – 5f—Syntheses of the “His*-Ser-pThr”–based type 5 macrocycles were 
achieved entirely on solid-phase. Ring sizes were determined by on–resin pThr-directed 
N(τ)–alkylation of peptides (16a–16c) with appropriate-length alcohols to give the 
corresponding series of bis-alkenyl-containing peptides (17a–17f) (Figure 4). Microwave 
irradiation was employed both for RCM macrocyclization (120 °C, 30 min) to yield the 
corresponding unsaturated macrocycles (18a–18f), and for the subsequent diimine double 
bond reduction (50 °C, 30 min). Cleavage of the saturated macrocycles (19a–19f) gave the 
desired final products 5a–5f, having ring sizes of 14-, 16-, 18-, 20-, 22- and 24-members, 
respectively (Figure 4).
Mass Spectral Characterization
We had previously verified the structures of on-resin Mitsunobu His* N(τ)-alkylation 
products by high-resolution liquid chromatography – tandem mass spectrometry 
(LC/MS/MS) analyses using electrospray ionization (ESI).2 We performed similar analyses 
for peptides of the current series. For all macrocyclic final products, both the protonated 
peptide (MH+) and the double-protonated peptide (M+2H)2+ ions were observed and had 
masses consistent with the expected elemental composition (see Supporting Information). 
Interestingly, the (M+2H)2+ ions of these macrocycles were of consistently lower relative 
abundance than those observed in the ESI mass spectra of their linear analogues reported 
earlier.2 The increased spatial constraint of these molecules may make multiple charging less 
energetically favored than with the linear pThr-containing pentapeptide derivatives. 
LC/MS/MS analysis also confirmed the presence of a free phosphate moiety and the absence 
of any macrocyclic derivatives resulting from RCM through the isomeric phosphate ester.
Typically, the primary low energy MS/MS fragmentation observed for pSer- and pThr-
containing peptides is loss of neutral phosphoric acid (H3PO4) or HPO3, with a much 
reduced fragmentation of the amide bond peptide backbone to generate b and y sequence-
indicating ions.28 The abundance of these ions depends on the charge-state of the precursor 
ion, the structure of the peptide and the nature of the collision-induced dissociation 
(CID).29,30 For the macrocyclic phosphopeptide 3c, which contains a ring-constrained, 
cationic bis-alkyl-His and a free phosphate, a predominant and diagnostic CID-mediated 
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neutral loss should be that of H3PO4 (98 da), resulting in a product ion at m/z 891.5702. 
Other prominent neutral losses are expected to be those that are related, such as MH+-HPO3 
and MH+-(H3PO4 + NH3), as well as MH+-NH3 from the C-terminal amide. These product 
ions are all observed in the MS/MS spectrum resulting from CID of the MH+ of 3c (Figure 5 
and Supporting Information). The bn and yn sequence-indicating ions for the macrocyclic 
pThr-containing peptide derivatives are also expected to be somewhat different from those of 
the linear analogues. Thus in the case of 3c, the bn ions that are seen are those that 
incorporate the cyclic His*-imidazolium cation, namely b’3 and b’4 (Figure 5). (Note that 
the b’n ions observed for this and other macrocycles are designated by a prime to indicate a 
localized charge and numbered on the basis of amino acid residues in the cyclic His*-
imidazolium cation.) Furthermore, because the macrocycle is formed through His*, no y3 
ions are seen for 3c, since cleavage at the Leu-His* amide bond no longer results in a 
distinct yn product ion. Thus, taken all together, the MS/MS spectrum of 3c (Figure 5) and 
those of the other macrocyclic derivatives (Supporting Information) support structures 
containing a free phosphate and a macrocyclic ring formed through a His*-imidazolium 
cation.
Determination of Plk1 PBD-binding Affinities
PBIP1 is a physiological substrate of Plk1, that once phosphorylated at Thr78, forms a Plk1–
PBIP1 complex through the interaction between the PBD of Plk1 and the pThr78 of 
PBIP1.31 Peptide 1 represents residues 74–78 of PBIP1. In order to determine their Plk1 
PBD-binding affinities, the synthetic macrocyclic peptides were evaluated in an enzyme-
linked immunosorbent assay (ELISA)-based assay that measured their ability to compete 
with an immobilized pThr78-derived peptide for binding to human influenza hemagglutinin-
green fluorescent protein (HA-GFP)- fused Plk1 expressed in HEK 293A cells. Consistent 
with our previous findings, introducing the N(π)–(CH2)8Ph group (peptide 2, IC50 = 12 nM) 
significantly increased binding affinity relative to the parent peptide (1, IC50 = 23 μM) 
(Table 1).4 In the type 3 macrocycles, peptides having 20– and 22–membered ring sizes (3b, 
IC50 = 15 nM and 3c, IC50 = 14 nM, respectively) bound with greater affinities than those 
having 18– and 24–member ring sizes (3a, IC50 = 140 nM and 3d, IC50 = 110 nM, 
respectively). For the type 4 macrocycles, affinities increased sequentially in going from the 
15–membered to the 20–membered ring sizes (from 4a, IC50 = 1.8 μM to 4c, IC50 = 140 
nM) and then decreased progressively as the ring size increased to 24–member (4e, IC50 = 
13 μM). None of the type 5 macrocycles bound with good affinity (Table 1).
X-Ray Co-crystal Studies
To understand the effects of macrocyclization on PBD binding modes, we obtained the Plk1 
PBD co-crystal structures of the highest affinity macrocycles (3b, 3c, and 4c) and compared 
these with the previously reported structure of the PBD-bound open-chain parent peptide 2 
[Protein Data Bank (PDB) accession code 3RQ7].4 By superimposing all structures using 
standard protocols included in MolSoft ICM Pro modeling software,32,33 we found that 
folding of the flexible ring-closing polymethylene chains resulted in striking correspondence 
with 2 in the binding orientations of the peptide portions of all macrocycles (Figure 6). 
Interactions were preserved within the pThr-binding pocket with the key phosphoryl-binding 
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residues His538 and Lys540.3,34 Consistent with previous reports that a hydrophobic region 
formed by the Trp414 and Phe535 residues are important in ligand binding,3,34,35 we 
observed that for the current complexes, the largest contact interactions occurred with the 
Trp414 residue. The contact surface areas for 3b and 3c were larger than with the parent 
peptide 2. Increased contact between the ligand Pro carbonyl and the Arg516 was also 
observed for 3b. Contact with the Phe535 residue was increased for 3c, where interactions 
with the ligand Pro pyrrolidine C4 and C5 methylenes as well as proximal components of 
the ring-closing chain were possible. In contrast, a dramatic loss of contact with Phe535 was 
incurred for 4c due to the absence of a ligand Pro residue.
MATERIALS AND METHODS
Materials
Fmoc-Leu-OH, Fmoc-Ser(Trt)-OH and Fmoc-Thr(PO(OBzl)OH)-OH, NovaSyn®TGR 
amide resin and NovaSyn® TG Siber resin were purchased from Novabiochem. Allyl 
alcohol, 3-butenoic acid, 3-buten-1-ol, cinnamyl alcohol, 9-decenoic acid, 9-decen-1-ol, 5-
hexenoic acid, 5-hexen-1-ol, 7-octenoic acid and 4-penten-1-ol were purchased from Sigma-
Aldrich. 6-Hepten-1-ol, 7-octen-1-ol and 8-nonen-1-ol were purchased from Tokyo 
Chemical Industry Co., Ltd. (TCI). Fmoc-His(N(π)-(CH2)8Ph)-OH,11 N-Fmoc (2S,4R)-4-
(allyloxy)pyrrolidine-2-carboxylic acid,36 N-Fmoc (2S,4R)-4-(pent-4-en-1-
yloxy)pyrrolidine-2-carboxylic acid36 and NBSH26 were prepared according to the indicated 
literature procedures.
Solid-phase Peptide Synthesis
Resin-bound open chain peptides 6a and 6b (Figure 2) were synthesized on NovaSyn® TG 
Siber resin, while peptides 12a and 12b (Figure 3) and 16(a – c) (Figure 4) were synthesized 
on NovaSyn®TGR resin following standard Fmoc-based solid-phase protocols using N-
methyl-2-pyrrolidone (NMP) as solvent. 1-O-Benzotriazole-N,N,N’,N’-tetramethyl-
uronium-hexafluoro-phosphate (HBTU) (5.0 equiv), hydroxybenzotriazole (HOBT) (5.0 
equiv) and N,N-diisopropylethylamine (DIPEA) (10.0 equiv) were used as coupling 
reagents. Amino terminal acetylation was achieved using 1-acetylimidazole (10 equiv) in 
DMF (4h) (for 6a and 6b), and appropriate alkenoic acids (5 equiv), HBTU (5.0 equiv), 
HOBt (5.0 equiv) and DIPEA (10 equiv) in NMP (2 h) [for 12a, 12b and 16 (a-c)].
Detailed Solid-phase Protocol (Synthesis of Peptide 6a)—NovaSyn® TG Siber 
resin (0.21 mmol/g, 476 mg, 0.1 mmol) was swelled (CH2Cl2, 5 mL, 1 h) and then washed 
thoroughly with DMF (5 mL × 5). The N-Fmoc group was removed by treating with 20% 
piepridine in DMF (4 mL, 20 minutes) and the resin was then washed with DMF (5 mL × 6). 
A solution of Fmoc-Thr(PO(OBzl)OH)-OH (256 mg, 0.5 mmol), HBTU (195 mg, 0.5 
mmol), HOBt (68 mg, 0.5 mmol) and DIPEA (0.174 mL, 1.0 mmol) in NMP (5 mL) was 
added and the resin was mixed by gentle rotation (2 h). The sequence of Fmoc-deprotection 
and coupling was completed with appropriate protected amino acids as specified in 
Materials. Following deprotection of the final residue, acetylation of the terminal amine was 
achieved using 1-acetylimidazole (110 mg, 1.0 mmol) in DMF (5 mL) (4 h). The resin was 
then washed with DMF (5 mL × 5); MeOH (5 mL × 5); CH2Cl2 (5 mL × 5) and diethyl ether 
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and the resin was dried under high vacuum to afford resin-bound peptide 6a (0.1 mmol). The 
syntheses of resin-bound peptides 6b, 12a, 12b, 16a, 16b and 16c were achieved similarly 
using appropriate amino acids as indicated in Materials.
Resin Cleavage
NovaSyn® TGR Resin: Resin-bound peptide was cleaved by treatment with trifluoroacetic 
acid (TFA): triispropylsilane (TIS) : H2O (95 : 2.5 : 2.5) at room temperature (4 h). The resin 
was removed by filtration and the filtrate was concentrated under vacuum. NovaSyn® TG 
Siber Resin: Resin bound peptide was cleaved by treatment with 1% TFA in CH2Cl2 at room 
temperature (5 min) and the resin was filtered and the filtrate collected. This procedure was 
repeated (5 x) and the combined filtrates were concentrated under vacuum.
HPLC Purification
Crude peptides (from 0.1 mmol resin) were dissolved in 50% aqueous CH3CN (5 mL) and 
purified by reverse phase preparative HPLC using a Phenomenex C18 column (21 mm dia × 
250 mm, cat. no: 00G-4436-P0) with a linear gradient from 30% aqueous CH3CN (0.1% 
TFA) to 100% CH3CN (0.1% TFA) over 30 min at a flow rate of 10.0 mL/min. 
Lyophilization gave the desired products as white amorphous solids.
On-resin Mistunobu N(τ)-His Alkylation
Resin-bound peptides 6a and 6b (Figure 2); 12a and 12b (Figure 3) and 16(a – c) (Figure 4) 
(0.1 mmol) were treated with triphenylphosphine (PPh3) (262 mg, 1.0 mmol), diethyl 
azidodicarboxylate (DEAD) (0.46 mL, 40% solution in toluene, 1.0 mol) and appropriate 
alcohols (1.0 mmol) in dry CH2Cl2 (4 mL) at room temperature (4 h). The resulting resin-
bound peptides [7(a – d) (Figure 2); 13(b – e) (Figure 3) or 17(a – f) (Figure 4)] were 
washed sequentially with DMF, MeOH, CH2Cl2 and Et2O and dried under vacuum.
On-resin Ring-closing Metathesis
To resin-bound peptide [7(b – d) (Figure 2); 13(b – e) (Figure 3) or 17(a – f) (Figure 4)] (0.1 
mmol) under helium was added degassed CH2Cl2:DMF (1:1; 4 mL) and the resin was 
allowed to swell (30 min). A solution of Hoveyda-Grubbs 2nd generation catalyst (Aldrich 
cat. No. 569755) (18.8 mg, 0.03 mmol) in degassed CH2Cl2:DMF (10:1; 0.2 mL) was added 
and the mixture was stirred under microwave irradiation (120 °C; 30 min). The resulting 
resins [8(b – d), Figure 2; 14(b – e), Figure 3 or 18(a – f), Figure 4] were washed 
sequentially with DMF, MeOH, CH2Cl2 and Et2O and dried under vacuum.
Solution Phase Ring-closing Metathesis
Resin-bound open-chain peptide 7a was cleaved from the resin and purified by HPLC as 
indicated above to yield peptide 10 (Figure 2). To the peptide under helium was added a 
solution of Hoveyda-Grubbs 2nd generation catalyst (0.5 equiv) 1 mM in degassed 
CH2Cl2:DMF (10:1) and the mixture was stirred at room temperature (24 h). Addition of 
catalyst (0.5 equiv) was repeated and the mixture was stirred at room temperature (24 h) and 
then concentrated under vacuum and purified by HPLC to yield 11a.
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On-resin Diimine Double Bond Reduction
To a solution of NBSH26 (0.44 g, 1 mmol) in anhydrous CH2Cl2 (10 mL) was added Et3N 
(0.56 mL, 2 mmol) and this was immediately added to resins [8(b – d), Figure 2; 14(b – e), 
Figure 3 or 18(a – f), Figure 4] (0.05 mmol) under helium. The mixture was subjected to 
microwave irradiation (50 °C; 30 min). The resulting resins [9(b – d), 15(b – e) and 19(a – 
f), respectively] were washed sequentially with DMF, MeOH, CH2Cl2 and Et2O and dried 
under vacuum. Resin cleavage and HPLC purification as indicated above provided the title 
peptides [3c and 3d; 4(b – e) and 5(a – f), respectively].
Solution-Phase Double Bond Reduction (Hydrogenation)
A solution of alkene-containing peptide (11a and 11b), 1 mM in DMF:THF (10:1) was 
hydrogenated over 10% Pd•C under H2 at room temperature (overnight). The mixture was 
filtered and the filtrate was concentrated under vacuum and purified by HPLC to yield the 
title peptides 3a and 3b, respectively.
Mass Spectral Characterization
Low resolution, positive ion, electrospray ionization (ESI) mass spectra were obtained by 
LC/MS analysis on an Agilent LC/MSD single quadrupole system that was also equipped 
with an in-line diode-array ultraviolet (UV) detector. A narrow-bore (100 × 2.1 mm), small-
particle (3.5-μm), Zorbax Rapid-Resolution reversed-phase C18 column coupled with a C18 
guard column (12.5 × 2.1 mm) was eluted with a 5–90% gradient of MeOH:H2O containing 
0.1% AcOH at a flow rate of 300 μL/min to separate the components of crude reaction 
isolates and purified final products. Background-subtracted mass spectra and the appropriate 
compound-indicating extracted ion chromatograms were generated using the LC/MSD 
ChemStation software (version B.04.02 SP1).
High-resolution LC/MS and LC/MS/MS analyses were conducted on a Thermo-Fisher LTQ-
XL Orbitrap hybrid mass spectrometer system operated under Xcalibur (version 2.1.0 SP1) 
control for data acquisition and qualitative analysis. A similar narrow-bore, small particle 
(3.5 μm) Zorbax Rapid-Resolution reversed-phase C18 column (100 × 2.1 mm) - guard 
column (12.5 × 2.1 mm) combination was eluted with CH3CN:H2O containing 0.1% AcOH 
at 250 μL/min. An initial linear gradient of 2–90% CH3CN:H2O over 15 min was followed 
by a 5 min isocratic hold at the final conditions before LC reset and equilibration (30 mi. 
cycle). Primary mass spectra (MS1) for accurate mass measurement of a molecular species 
([M+H]+, [M+Na]+ or [M+2H]+2) were obtained at a resolution of 30,0000 (full width at 
half maximum), while MS/MS (MS2) studies employing collision-induced dissociation 
(CID) or higher energy CID (HCD) were conducted at a resolution of 15,000. For these MS2 
studies, [M+H]+ or [M+2H]+2 precursor ions were selected using a mass window that 
encompassed the isotopic profile of the ion of interest. For the compounds in question, CID 
and HCD were carried out at an optimized energy setting of 30 and 27.5, respectively, in 
order to give the highest intensity product ion mass spectrum. Product ion spectra containing 
multiply charged ions (i.e., those from [M+2H]+2 precursors) were deconvoluted to a single 
charge state using the Xtract software module of Xcalibur in order to facilitate structural 
assignment and analysis. In the case of selected open-chain macrocyclic precursors (e.g., 
compound 7c), MS2 high-resolution extracted ion chromatograms (HR-XICs) were 
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generated post-analysis using a 20 or 30 mDa mass window centered on the observed 
accurate mass of the appropriate diagnostic ions. These HR-XICs were then used to locate 
and measure the relative amounts of isomeric bis-alkyl-His-containing phosphopeptide and 
esterified histidyl phosphopeptide present in the crude precyclized isolates. MS/MS 
structural assignments are as indicated in Figure 2, which is the MS/MS product ion mass 
spectrum resulting from the CID fragmentation of the [M+H]+ ion of 3b. A summary of the 
high resolution MS1 and MS2 data for each compound can be found in the Supporting 
Information.
X-ray Crystallography
Crystallization of Macrocycle-PBD Complexes—Plk1 PBD protein (residues 371–
603) was obtained from Dr. Dan Lim who purified it as previously described.3 Frozen stocks 
of protein at 37 mg/mL in 10 mM Tris pH 8, 0.5 M NaCl, 10 mM dithiothreitol (DTT)were 
thawed and diluted to 10 mg/mL with the same buffer. Complexes with each of three 
macrocycle compounds (3b, 3c and 4b) were prepared by adding 100 mM stocks of the 
macrocycle in dimethylsulfoxide (DMSO) directly to the diluted protein to achieve a final 
concentration of 1 mM. Crystals were grown by hanging drop vapor diffusion, with drops 
made by mixing equal volumes of protein-macrocycle complex and well solution containing 
2–6% polyethylene glycol (PEG)-3350. Crystals were cryo-protected by quickly dipping in 
a solution of 37.5% ethylene glycol in well solution and frozen in liquid nitrogen.
Structure Solution and Refinement—X-ray diffraction data were collected at the 
Advance Proton Source (APS) using the Northeastern Collaborative Access Team (NE-CAT) 
24-ID-C beam line. Data were indexed, integrated and scaled using HKL2000.37 All crystals 
belonged to the space group P21 with nearly identical unit cell parameters. The structures 
were solved by molecular replacement using PHASER38 with PDB entry 4DFW (minus 
solvent and bound ligand) as a search model. The models were built with COOT39 and 
refined using PHENIX.40 Refinement constraints for the bound macrocycle ligands were 
generated by the GRADE web server (http://grade.globalphasing.org). Data collection and 
refinement statistics are in the Supporting Information.
ELISA-based PBD-binding Inhibition Assays
Similar to previously reported procedures,3,4 biotinylated p-T78 peptide was first diluted 
with 1 × coating solution (KPL Inc., Gaithersburg, MD) to the final concentration of 0.3 μM, 
and then 100 μL of the resulting solution was immobilized onto a 96-well streptavidin-
coated plate (Nalgene Nunc, Rochester, NY). The wells were washed once with phosphate 
buffered saline (PBS) plus 0.05% Tween20 (PBST), and incubated with 200 μL of PBS plus 
1% bovine serum albumin (BSA) (blocking buffer) for 1 h to prevent non-specific binding. 
Mitotic 293A lysates expressing HA-EGFP-Plk1 were prepared in TBSN buffer [20mM 
Tris-Cl (pH 8.0), 150 mM NaCl, 0.5% Nonidet P-40, 5 mM EGTA, 1.5 mM EDTA, 20 mM 
p-nitrophenyl phosphate, and protease inhibitor mixture (Roche)] (~ 60 μg total lysates in 
100 μl buffer), mixed with the indicated amount of the competitors (p-T78 peptide and its 
derivative compounds), provided immediately onto the biotinylated peptide-coated ELISA 
wells, and then incubated with constant rocking for 1 h at 25 °C. Following the incubation, 
ELISA plates were washed 4 × with PBST. To detect bound HA-EGFP-Plk1, the plates were 
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probed for 2 h with 100 μL/well of anti-HA antibody at a concentration of 0.5 μg/mL in 
blocking buffer and then washed 5 ×. The plates were further probed for 1 h with100 μL/
well of horse radish peroxidase (HRP)-conjugated secondary antibody (GE Healthcare, 
Piscataway, NJ) at a 1:1,000 dilution in blocking buffer. The plates were washed 5 × with 
PBST and incubated with 100 μL/well of 3,3′,5,5′-tetramethylbenzidine (TMB) solution 
(Sigma, St. Louis, MO) as a substrate until a desired absorbance was reached. The reactions 
were stopped by the addition of 100 μL/well of stop solution (Cell Signaling Technology, 
Danvers, MA). The optical density (O.D.) was measured at 450 nm by using an ELISA plate 
reader (Molecular Devices, Sunnyvale, CA). Calculated IC50 values are listed in Figure 1 
and Table 1.
CONCLUSION
The ability of neighboring acidic residues to facilitate Mitsunobu N(τ)–alkylation of His 
residues bearing an N(π)–alkyl group provides a useful means of specific structural 
modification that opens a range of applications. Our use of the bis-alkyl-His imidazolium 
ring for the synthesis of charge-masked macrocyclic phosphopeptides provides one example 
of an application to biologically important protein-protein interactions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Structures of target PBD-binding peptides with Plk1 PBD-binding affinities.
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Figure 2. Reagents and Conditions
i) ROH (10 eq.), PPh3 (10.0 eq.), DEAD (10.0 eq.), CH2Cl2, 4 h; ii) Hoveyda-Grubbs 2nd 
generation cat. (0.3 eq.), CH2Cl2/DMF (10:1, degassed), microwave, 120 °C, 30 min; iii) 
NBSH (20 eq.), Et3N (40 eq.), CH2Cl2, microwave, 50 °C, 30min; iv) TFA/H2O/TIS = 95: 
2.5: 2.5, 4 h; v) 1% TFA in CH2Cl2; vi)) Hoveyda-Grubbs 2nd generation cat. (0.5 eq.), 
CH2Cl2/DMF (10:1, degassed), room temp., 24 h (two-times); vii) H2, 10% Pd•C, 
THF/DMF (10:1), overnight.
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Figure 3. Reagents and Conditions
i) ROH (10 eq.), PPh3 (10.0 eq.), DEAD (10.0 eq.), CH2Cl2, 4 h; ii) Hoveyda-Grubbs 2nd 
generation cat. (0.3 eq.), CH2Cl2/DMF (10:1, degassed), microwave, 120 °C, 30 min; iii) 
NBSH (20 eq.), Et3N (40 eq.), CH2Cl2, microwave, 50 °C, 30 min; iv) TFA/H2O/TIS = 95: 
2.5: 2.5, 4 h.
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Figure 4. Reagents and Conditions
i) ROH (10 eq.), PPh3 (10.0 eq.), DEAD (10.0 eq.), CH2Cl2, 4 h; ii) Hoveyda-Grubbs 2nd 
generation cat. (0.3 eq.), CH2Cl2/DMF (10:1, degassed), microwave, 120 °C, 30 min; iii) 
NBSH (20 eq.), Et3N (40 eq.), CH2Cl2, microwave, 50 °C, 30 min; iv) TFA/H2O/TIS = 95: 
2.5: 2.5, 4 h.
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Figure 5. 
Partial, high resolution, CID MS/MS mass spectrum of the MH+ of 3c. The presence of a 
free phosphate moiety is indicated by the product ions corresponding to MH+-HPO3, MH+-
H3PO4, and MH+-(H3PO4 + NH3). Insert: Structure and expected CID fragmentation of the 
MH+ (m/z 989.5471) of 3c.
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Figure 6. 
X-ray crystal structures of Plk1 PBD-bound ligands. (A) Protein ribbon rendition of PBD-
bound 2 (PDB: 3RQ7) with key interacting protein residues shown and the structures of 
PBD-bound macrocycles 3b, 3c and 4c superimposed. (B) Enlargement of overlaid PBD-
bound peptides shown in (A). For both (A) and (B) ligand coloring is as indicated.
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Table 1
Plk1 PBD IC50 values measured in an ELISA competition assay.a
No. Ring Size IC50 (μM)
1 – 29
2 – 0.011
3a 18 0.14
3b 20 0.015
3c 22 0.014
3d 24 0.11
4a 15 1.8
4b 18 0.83
4c 20 0.14
4d 22 0.24
4e 24 13
5a 14 19
5b 16 9.4
5c 18 29
5d 20 25
5e 22 99
5f 24 200
aValues were obtained in an ELISA-based assay that measured the ability of peptides to compete with an immobilized pT78 peptide for binding to 
HEK 293A cell lysate-derived GFP-HA-fused Plk1.
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